This invention relates to compounds which are generally EP4 receptor
agonists and which are represented by Formula I:
##STR1##
wherein A is a CH2CH2, or CHCH;
B is absent, an aryl, or heteroaryl group; R1 is alkyl, alkenyl, alkynyl,
cycloalkylalkyl, heterocyclylalkyl, aryl, arylalkyl or heteroaryl, when B is aryl
or heteroaryl and R3, R4, R5 and R6 are
not simultaneously hydrogen, or R1 is heterocyclylalkyl, aryl, or heteroaryl
when B is absent and R3, R4, R5 and R6 are
simultaneously hydrogen; and the other substituents are as defined in the specification;
or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically
acceptable salts or solvates thereof. The invention further relates to pharmaceutical
compositions containing such compounds, methods for their use as therapeutic agents,
and methods of preparation thereof.
